Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2015

View Archived Issues

Genentech's LGR5-targeting ADC inhibits growth of colon cancer

SMRX-11: A clot-specific streptokinase

Novel CSF-1R inhibitor shows promising results for bone tumors

Italian and U.S. academic team patents ASAH1 inhibitors

AbbVie patents V1bR ligands

Chengdu Bestchiralbio announces DPP IV inhibitors

Roche reports anti-HBV agents

Eisai presents splicing factor 3B modulators

Calitor Sciences and Sunshine Lake Pharma present PI3K inhibitors

European Comission approves Horizon's Ravicti

Managed access program for ixazomib begins for patients with multiple myeloma

Heptares enters strategic drug discovery collaboration with Pfizer

Vericiguat holds promise for heart failure

Applications seeking approval of Stelara for Crohn's disease submitted by Janssen

Dose expansion implemented in study of immunomodulator EF-022 in patients with solid tumors

Phase I study of Intercept's INT-767 begins

FDA approves Empliciti for previously treated multiple myeloma

Novel kinase inhibitor shows promise for the treatment of HCC

Valneva releases data from phase II study of prophylactic C. difficile vaccine candidate

Phase III results for MD-1003 in MS patients with chronic visual loss following optic neuritis

Almirall to acquire dermatology specialist Poli Group

Puma Biotechnology reports plans for neratinib MAA filing

Roche licenses Proximagen VAP-1 inhibitor for inflammatory disease

Baxalta's Adynovate launched for the treatment of hemophilia in adult patients

Mallinckrodt closes sale of CMDS business to Guerbet

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...